328 related articles for article (PubMed ID: 27757845)
1. Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease.
Zhang X; Wang Y; Liu P
Protein Cell; 2017 Jan; 8(1):4-13. PubMed ID: 27757845
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease.
Su W; Wang Y; Jia X; Wu W; Li L; Tian X; Li S; Wang C; Xu H; Cao J; Han Q; Xu S; Chen Y; Zhong Y; Zhang X; Liu P; Gustafsson JÅ; Guan Y
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11437-42. PubMed ID: 25028495
[TBL] [Abstract][Full Text] [Related]
3. Role of HSD17B13 in the liver physiology and pathophysiology.
Su W; Mao Z; Liu Y; Zhang X; Zhang W; Gustafsson JA; Guan Y
Mol Cell Endocrinol; 2019 Jun; 489():119-125. PubMed ID: 30365983
[TBL] [Abstract][Full Text] [Related]
4. Liver X receptor α induces 17β-hydroxysteroid dehydrogenase-13 expression through SREBP-1c.
Su W; Peng J; Li S; Dai YB; Wang CJ; Xu H; Gao M; Ruan XZ; Gustafsson JÅ; Guan YF; Zhang XY
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E357-E367. PubMed ID: 28270440
[TBL] [Abstract][Full Text] [Related]
5. Hydroxysteroid dehydrogenase family proteins on lipid droplets through bacteria, C. elegans, and mammals.
Liu Y; Xu S; Zhang C; Zhu X; Hammad MA; Zhang X; Christian M; Zhang H; Liu P
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):881-894. PubMed ID: 29702244
[TBL] [Abstract][Full Text] [Related]
6. Genomics of human fatty liver disease reveal mechanistically linked lipid droplet-associated gene regulations in bland steatosis and nonalcoholic steatohepatitis.
Sahini N; Borlak J
Transl Res; 2016 Nov; 177():41-69. PubMed ID: 27376874
[TBL] [Abstract][Full Text] [Related]
7. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD.
Mashek DG
Mol Metab; 2021 Aug; 50():101115. PubMed ID: 33186758
[TBL] [Abstract][Full Text] [Related]
8. 17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease.
Wang MX; Peng ZG
Pharmacol Ther; 2023 Jun; 246():108428. PubMed ID: 37116587
[TBL] [Abstract][Full Text] [Related]
9. Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.
Breher-Esch S; Sahini N; Trincone A; Wallstab C; Borlak J
BMC Med Genomics; 2018 Dec; 11(1):111. PubMed ID: 30547786
[TBL] [Abstract][Full Text] [Related]
10. Hepatic lipid droplet homeostasis and fatty liver disease.
Seebacher F; Zeigerer A; Kory N; Krahmer N
Semin Cell Dev Biol; 2020 Dec; 108():72-81. PubMed ID: 32444289
[TBL] [Abstract][Full Text] [Related]
11. Exercise regulation of hepatic lipid droplet metabolism.
Pino-de la Fuente F; Bórquez JC; Díaz-Castro F; Espinosa A; Chiong M; Troncoso R
Life Sci; 2022 Jun; 298():120522. PubMed ID: 35367244
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
[TBL] [Abstract][Full Text] [Related]
13. A new perspective on NAFLD: Focusing on lipid droplets.
Scorletti E; Carr RM
J Hepatol; 2022 Apr; 76(4):934-945. PubMed ID: 34793866
[TBL] [Abstract][Full Text] [Related]
14. Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.
Lim JW; Dillon J; Miller M
World J Gastroenterol; 2014 Jul; 20(26):8325-40. PubMed ID: 25024592
[TBL] [Abstract][Full Text] [Related]
15. Bergamot polyphenol fraction prevents nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of metabolic syndrome.
Parafati M; Lascala A; Morittu VM; Trimboli F; Rizzuto A; Brunelli E; Coscarelli F; Costa N; Britti D; Ehrlich J; Isidoro C; Mollace V; Janda E
J Nutr Biochem; 2015 Sep; 26(9):938-48. PubMed ID: 26025327
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of lipid droplet proteins in liver diseases.
Carr RM; Ahima RS
Exp Cell Res; 2016 Jan; 340(2):187-92. PubMed ID: 26515554
[TBL] [Abstract][Full Text] [Related]
17. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease.
Basu Ray S
Adipocyte; 2019 Dec; 8(1):201-208. PubMed ID: 31062641
[TBL] [Abstract][Full Text] [Related]
18. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
[TBL] [Abstract][Full Text] [Related]
19. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
20. Lipophagy: A potential therapeutic target for nonalcoholic and alcoholic fatty liver disease.
Han YH; He XM; Jin MH; Sun HN; Kwon T
Biochem Biophys Res Commun; 2023 Sep; 672():36-44. PubMed ID: 37336123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
